Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Tax ProvisionsTax Rate
Others
Ratios

Lexaria Bioscience (LEXX) Depreciation & Amortization - Total (2017 - 2021)

Historic Depreciation & Amortization - Total for Lexaria Bioscience (LEXX) over the last 8 years, with Q2 2021 value amounting to $27929.0.

  • Lexaria Bioscience's Depreciation & Amortization - Total fell 54.13% to $27929.0 in Q2 2021 from the same period last year, while for Feb 2022 it was $27929.0, marking a year-over-year decrease of 7524.35%. This contributed to the annual value of $112750.0 for FY2020, which is 8620.97% up from last year.
  • Lexaria Bioscience's Depreciation & Amortization - Total amounted to $27929.0 in Q2 2021, which was down 54.13% from $27930.0 recorded in Q1 2021.
  • In the past 5 years, Lexaria Bioscience's Depreciation & Amortization - Total ranged from a high of $28875.0 in Q3 2020 and a low of $375.0 during Q4 2017
  • Its 5-year average for Depreciation & Amortization - Total is $18495.2, with a median of $26853.5 in 2019.
  • Its Depreciation & Amortization - Total has fluctuated over the past 5 years, first surged by 420094.88% in 2019, then crashed by 124.46% in 2021.
  • Quarter analysis of 5 years shows Lexaria Bioscience's Depreciation & Amortization - Total stood at $375.0 in 2017, then surged by 327.47% to $1603.0 in 2018, then soared by 1616.28% to $27512.0 in 2019, then increased by 1.52% to $27929.0 in 2020, then changed by 0.0% to $27929.0 in 2021.
  • Its last three reported values are $27929.0 in Q2 2021, $27930.0 for Q1 2021, and $27929.0 during Q4 2020.